News

New data on Radium 223 presented at ASCO

Publish date: June 2, 2013
By
Mary Jo Dales

 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO – Dr. Nicholas Vogelzang, investigator on the ALSYMPCA trial, discusses new data on Radium 223 (Xofigo) and new research on castration-resistant metastatic prostate cancer at the ASCO Annual Meeting 2013.

Recommended Reading

FDA approves radiotherapy for metastatic prostate cancer
MDedge Hematology and Oncology
Postop surveillance sufficient for stage I testicular cancer
MDedge Hematology and Oncology
Consequences of not screening for prostate cancer prove dire
MDedge Hematology and Oncology
New test beats PSA in predicting significant prostate Ca
MDedge Hematology and Oncology
Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index
MDedge Hematology and Oncology
Malignant phyllodes tumor of the prostate and seminal vesicle: an unusual presentation
MDedge Hematology and Oncology
Utilization of radiotherapy services by a palliative care unit: pattern and implication
MDedge Hematology and Oncology
No higher risk of cancer after 9 years of testosterone replacement therapy
MDedge Hematology and Oncology
Novel biomarker may measure prostate cancer aggressiveness
MDedge Hematology and Oncology
Prostatectomy follow-up guidelines released
MDedge Hematology and Oncology